Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer.
Title: | Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer. |
---|---|
Authors: | de Mooij, Cornelis M., van Nijnatten, Thiemo J. A., Goorts, Briete, Kooreman, Loes F. S., Raymakers, Isabel W. M., van Meijl, Silke P. L., de Boer, Maaike, Keymeulen, Kristien B. M. I., Wildberger, Joachim E., Mottaghy, Felix M., Lobbes, Marc B. I., Smidt, Marjolein L. |
Source: | Cancers; Jan2023, Vol. 15 Issue 2, p401, 15p |
Subject Terms: | CONFIDENCE intervals, CANCER chemotherapy, LYMPH nodes, METASTASIS, MAGNETIC resonance imaging, QUANTITATIVE research, MANN Whitney U Test, QUALITATIVE research, RADIOPHARMACEUTICALS, RESEARCH funding, DEOXY sugars, COMBINED modality therapy, RECEIVER operating characteristic curves, DATA analysis software, BREAST tumors, EMISSION-computed tomography, LONGITUDINAL method |
Abstract: | Simple Summary: Neoadjuvant chemo(targeted) therapy (NCT) can downstage disease burden in breast cancer, allowing less invasive surgery. The ability of sequential hybrid [18F]FDG PET/MRI to predict the final pathologic primary tumour response to NCT in breast cancer was investigated. In addition, the value of sequential hybrid [18F]FDG PET/MRI in predicting axillary response was investigated separately in clinically node-positive breast cancer patients. In this study, final pathologic primary tumour and axillary lymph node response prediction with qualitative or quantitative [18F]FDG PET/MRI after NCT is not reliable. However, combining the relative decrease in [18F]FDG PET and MR imaging variables halfway through NCT improved diagnostic performance, especially in predicting the final pathologic axillary lymph node response. These findings suggest that sequential hybrid [18F]FDG PET/MRI could have complementary value in the early prediction of the final pathologic response to NCT in breast cancer. Background: The aim of this study was to investigate whether sequential hybrid [18F]FDG PET/MRI can predict the final pathologic response to neoadjuvant chemo(targeted) therapy (NCT) in breast cancer. Methods: Sequential [18F]FDG PET/MRI was performed before, halfway through and after NCT, followed by surgery. Qualitative response evaluation was assessed after NCT. Quantitatively, the SUV |
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
Database: | Complementary Index |
Full text is not displayed to guests. | Login for full access. |
Be the first to leave a comment!